Baird raised the firm’s price target on Iqvia (IQV) to $196 from $159 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- IQVIA Holdings: Balancing Growth in TAS with R&DS Challenges and Economic Pressures Warrants Hold Rating
- IQVIA Holdings: Strong Performance, Growth Potential, and Competitive Advantages Justify Buy Rating and Increased Price Target
- Iqvia price target raised to $185 from $165 at Barclays
- Positive Outlook on IQVIA Holdings Amid Strong Q2 Performance and Competitive Positioning
- Strategic Positioning and Growth in Biotech: Justifying IQVIA Holdings’ Buy Rating